Suppr超能文献

解析防止白细胞介素-13介导的氧化应激诱导多巴胺能神经元细胞死亡增强的途径。

Deciphering the pathways that protect from IL-13-mediated potentiation of oxidative stress-induced dopaminergic nerve cell death.

机构信息

The Salk Institute for Biological Studies, 10010 N. Torrey Pines Rd., La Jolla, CA 92037, United States.

The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, CA 92037, United States.

出版信息

Cytokine. 2018 Mar;103:114-120. doi: 10.1016/j.cyto.2017.09.018. Epub 2017 Sep 30.

Abstract

The majority of Parkinson's disease (PD) cases are sporadic with only about 10% of PD patients having a family history of the disease suggesting that this neurodegenerative disorder is the result of both environmental and genetic factors. Both oxidative stress and neuroinflammation are thought to contribute to PD. Previously, we showed that the activation of interleukin 13 receptor alpha 1 (IL-13Rα1) increases the sensitivity of dopaminergic neurons to oxidative damage both in cultured cells and in animals. In this study, we investigated the pathways involved in the IL-13-mediated potentiation of oxidative stress-induced dopaminergic cell death using a combination of cell survival assays and Western blotting with appropriate antibodies. In addition, siRNA was used to examine the role of 4E-BP1 in this cell toxicity paradigm. We show that activation of both the Jak-Stat and PI3 kinase-mTOR pathways play key roles in the promotion of cell death by IL-13 in the presence of mild oxidative stress. The Jak 1/2 inhibitor ruxolitinib, the mTOR inhibitor rapamycin and the PI3 kinase inhibitor LY294002 all prevented the potentiation of cell death by IL-13. Moreover, 4E-BP1, a target of mTOR, appeared to mediate the protective effects of rapamycin. Together, these results indicate that multiple signaling pathways downstream of IL-13Rα1 activation play a role in the toxic effects of IL-13 in dopaminergic neurons in the presence of mild oxidative stress and suggest that any of these pathways might provide potential targets for the treatment of PD.

摘要

大多数帕金森病 (PD) 病例为散发性,只有约 10%的 PD 患者有家族病史,这表明这种神经退行性疾病是环境和遗传因素共同作用的结果。氧化应激和神经炎症都被认为与 PD 有关。之前,我们已经表明白细胞介素 13 受体 alpha1(IL-13Rα1)的激活会增加多巴胺能神经元对氧化损伤的敏感性,无论是在培养细胞中还是在动物中。在这项研究中,我们使用细胞存活测定和适当的抗体进行 Western blot 分析,研究了 IL-13 介导的氧化应激诱导的多巴胺能神经元死亡增强作用所涉及的途径。此外,还使用 siRNA 来研究 4E-BP1 在这种细胞毒性范例中的作用。我们发现,Jak-Stat 和 PI3 激酶-mTOR 途径的激活在轻度氧化应激存在下,IL-13 促进细胞死亡中起着关键作用。Jak 1/2 抑制剂芦可替尼、mTOR 抑制剂雷帕霉素和 PI3 激酶抑制剂 LY294002 均可阻止 IL-13 对细胞死亡的增强作用。此外,mTOR 的靶标 4E-BP1 似乎介导了雷帕霉素的保护作用。综上所述,这些结果表明,IL-13Rα1 激活下游的多个信号通路在轻度氧化应激存在下,在多巴胺能神经元中发挥 IL-13 的毒性作用,并表明这些通路中的任何一条都可能成为 PD 治疗的潜在靶点。

相似文献

10
mTOR Signaling in Parkinson's Disease.mTOR 信号通路在帕金森病中的作用
Neuromolecular Med. 2017 Mar;19(1):1-10. doi: 10.1007/s12017-016-8417-7. Epub 2016 Jun 4.

引用本文的文献

本文引用的文献

4
Neuroimmunology of the Interleukins 13 and 4.白细胞介素13和4的神经免疫学
Brain Sci. 2016 Jun 13;6(2):18. doi: 10.3390/brainsci6020018.
6
Commentary: IL-4 and IL-13 receptors and signaling.述评:白细胞介素-4和白细胞介素-13受体与信号传导
Cytokine. 2015 Sep;75(1):38-50. doi: 10.1016/j.cyto.2015.05.023. Epub 2015 Jul 14.
10
Advances in kinase targeting: current clinical use and clinical trials.激酶靶向治疗的进展:当前的临床应用和临床试验。
Trends Pharmacol Sci. 2014 Nov;35(11):604-20. doi: 10.1016/j.tips.2014.09.007. Epub 2014 Oct 10.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验